Valuation: Polaris Group

Market Cap 11.65B 366M 321M 296M 276M 520M 34.63B 529M 3.55B 1.38B 17.09B 1.38B 1.35B 59.53B P/E 2024
-13.6x
P/E 2025 -6.1x
Enterprise Value 12.17B 382M 335M 309M 288M 543M 36.16B 553M 3.71B 1.44B 17.85B 1.44B 1.4B 62.17B EV / Sales 2024
318x
EV / Sales 2025 603x
Free-Float
34.02%
Yield 2024 *
-
Yield 2025 -
1 day+2.26%
1 week+3.44%
1 month+0.37%
3 months-29.24%
6 months-56.43%
Current year-56.43%
1 week 12.5
Extreme 12.5
13.6
1 month 12.5
Extreme 12.5
13.75
Current year 12.5
Extreme 12.5
35.95
1 year 12.5
Extreme 12.5
44.55
3 years 12.5
Extreme 12.5
91.1
5 years 12.5
Extreme 12.5
232
10 years 9.5
Extreme 9.5
232
Manager TitleAgeSince
Director of Finance/CFO - 01/03/2019
Chief Operating Officer - 01/02/2019
Chief Executive Officer - 01/05/2014
Director TitleAgeSince
Director/Board Member 78 -
Chairman 64 24/11/2014
Director/Board Member 75 25/02/2020
Change 5-day change 1-year change 3-year change Capi.($)
+2.26%+3.44%-64.90%-83.39% 357M
+1.15%+5.94%-3.40%+2.32% 46.62B
-2.77%+10.48%+409.05%+600.11% 40.95B
-0.03%+12.81%+22.61%-14.04% 32.26B
-1.73%+3.20%+17.72%+59.83% 32.24B
-3.29%+7.98%+14.01%+29.96% 25.53B
+1.15%+11.79% - - 16.38B
-0.96%+11.85%+68.73%+120.51% 15.27B
+0.56%+5.09%+13.43%+17.88% 13.61B
-1.74%+4.34%+100.68%+93.25% 13.34B
Average -0.54%+6.77%+64.22%+91.83% 23.65B
Weighted average by Cap. -0.89%+7.70%+94.48%+137.26%

Financials

2024 2025
Net sales 107M 3.36M 2.94M 2.72M 2.53M 4.78M 318M 4.86M 32.6M 12.65M 157M 12.64M 12.35M 547M 40.6M 1.28M 1.12M 1.03M 962K 1.81M 121M 1.84M 12.37M 4.8M 59.54M 4.79M 4.69M 207M
Net income -2.5B -78.66M -68.85M -63.56M -59.29M -112M -7.44B -114M -762M -296M -3.67B -296M -289M -12.79B -3.93B -123M -108M -99.74M -93.03M -175M -11.67B -178M -1.2B -464M -5.76B -464M -453M -20.06B
Net Debt 9.19M 289K 253K 233K 218K 410K 27.32M 418K 2.8M 1.09M 13.48M 1.09M 1.06M 46.96M 517M 16.25M 14.22M 13.13M 12.25M 23.07M 1.54B 23.48M 157M 61.13M 758M 61.04M 59.68M 2.64B
Logo Polaris Group
The Polaris Group, LLC is a Cayman Islands-based company, which is primarily engaged in biotechnology services, drug testing, contract development and manufacturing services and research, development, manufacture and sales of new drugs. The Company’s core research is ADI-PEG 20, which is undergoing human clinical trials for various cancer indications. The ADI-PEG 20 is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia, and others. ADI-PEG 20 is a biological drug produced by coupling arginine deiminase and polyethylene glycol with a molecular weight of 20,000.
Employees
-
Date Price Change Volume
30/06/26 TWD 13.55 +2.26% 1,274,774
29/06/26 TWD 13.25 +6.00% 1,513,600
26/06/26 TWD 12.50 -4.21% 2,171,938
25/06/26 TWD 13.05 -3.69% 1,246,733
24/06/26 TWD 13.55 +3.44% 1,260,121
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. 6550 Stock